Tracon Pharmaceuticals Stock Today
| TCON Stock | USD 1.89 0.04 2.16% |
Performance0 of 100
| Odds Of DistressOver 70
|
TRACON Pharmaceuticals is selling at 1.89 as of the 25th of April 2024; that is 2.16 percent up since the beginning of the trading day. The stock's open price was 1.85. TRACON Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for TRACON Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of January 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of January 2015 | Category Healthcare | Classification Health Care |
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California. The company has 2.28 M outstanding shares of which 744.91 K shares are at this time shorted by private and institutional investors with about 0.11 trading days to cover. More on TRACON Pharmaceuticals
Moving together with TRACON Stock
| 0.67 | BMY | Bristol Myers Squibb Earnings Call Today | PairCorr |
Moving against TRACON Stock
| 0.41 | ELYM | Eliem Therapeutics | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Financial Report 8th of May 2024
TRACON Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. TRACON Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding TRACON Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Charles Theuer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering TRACON Pharmaceuticals report their recommendations after researching TRACON Pharmaceuticals' financial statements, talking to executives and customers, or listening in on TRACON Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering TRACON Pharmaceuticals. The TRACON consensus assessment is calculated by taking the average forecast from all of the analysts covering TRACON Pharmaceuticals. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to TRACON Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, TRACON Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of TRACON Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TRACON Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to TRACON Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand TRACON Pharmaceuticals' financial leverage. It provides some insight into what part of TRACON Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TRACON Pharmaceuticals (TCON) is traded on NASDAQ Exchange in USA. It is located in 4350 La Jolla Village Drive, San Diego, CA, United States, 92122 and employs 17 people. TRACON Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.32 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate TRACON Pharmaceuticals's market, we take the total number of its shares issued and multiply it by TRACON Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. TRACON Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.28 M outstanding shares of which 744.91 K shares are at this time shorted by private and institutional investors with about 0.11 trading days to cover.
TRACON Pharmaceuticals currently holds about 13.58 M in cash with 3.68 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.63.
Check TRACON Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationAlmost 86.0 % of TRACON Pharmaceuticals outstanding shares are held by general public with 2.59 percent owned by insiders and only 11.66 (percent) by institutions.
Check TRACON Ownership Details
TRACON Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of TRACON Pharmaceuticals jumping above the current price in 90 days from now is about 88.81%. The TRACON Pharmaceuticals probability density function shows the probability of TRACON Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 4.0456. This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, TRACON Pharmaceuticals will likely underperform. Additionally, tRACON Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of TRACON Pharmaceuticals to move above the current price in 90 days from now is about 88.81 (This TRACON Pharmaceuticals probability density function shows the probability of TRACON Stock to fall within a particular range of prices over 90 days) .
TRACON Stock Institutional Holders
Institutional Holdings refers to the ownership stake in TRACON Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of TRACON Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing TRACON Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Ci Private Wealth Llc | 2023-12-31 | 57.5 K | |
| Northern Trust Corp | 2023-12-31 | 21.7 K | |
| Hoylecohen, Llc | 2023-12-31 | 13 K | |
| Tower Research Capital Llc | 2023-12-31 | 10.4 K | |
| Bank Of New York Mellon Corp | 2023-12-31 | 10.3 K | |
| Cutler Group Lp | 2023-12-31 | 1.2 K | |
| Qube Research & Technologies | 2023-12-31 | 800 | |
| Truvestments Capital Llc | 2023-12-31 | 318 | |
| Royal Bank Of Canada | 2023-12-31 | 251 | |
| Ikarian Capital, Llc | 2023-12-31 | 2.8 M | |
| Acadian Asset Management Llc | 2023-12-31 | 413.9 K |
TRACON Pharmaceuticals Historical Income Statement
TRACON Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting TRACON's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of TRACON Pharmaceuticals revenue and expense. TRACON Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, TRACON Pharmaceuticals' Total Other Income Expense Net is very stable compared to the past year. As of the 25th of April 2024, Total Revenue is likely to grow to about 12.6 M, while Operating Income is likely to drop (7.2 M). View More FundamentalsTRACON Stock Against Markets
Picking the right benchmark for TRACON Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in TRACON Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for TRACON Pharmaceuticals is critical whether you are bullish or bearish towards TRACON Pharmaceuticals at a given time. Please also check how TRACON Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in TRACON Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Stocks Directory Now
Stocks DirectoryFind actively traded stocks across global markets |
| All Next | Launch Module |
TRACON Pharmaceuticals Corporate Directors
TRACON Pharmaceuticals corporate directors refer to members of a TRACON Pharmaceuticals board of directors. The board of directors generally takes responsibility for the TRACON Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of TRACON Pharmaceuticals' board members must vote for the resolution. The TRACON Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Theodore Wang | Director | Profile | |
| Martin Mattingly | Independent Director | Profile | |
| William LaRue | Independent Director | Profile | |
| Alfred Scheidegger | Independent Director | Profile |
How to buy TRACON Stock?
Before investing in TRACON Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in TRACON Pharmaceuticals. To buy TRACON Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of TRACON Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase TRACON Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located TRACON Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased TRACON Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as TRACON Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy TRACON Stock please use our How to Invest in TRACON Pharmaceuticals guide.
Already Invested in TRACON Pharmaceuticals?
The danger of trading TRACON Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of TRACON Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than TRACON Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile TRACON Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether TRACON Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of TRACON Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tracon Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tracon Pharmaceuticals Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TRACON Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TRACON Stock, please use our How to Invest in TRACON Pharmaceuticals guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for TRACON Stock analysis
When running TRACON Pharmaceuticals' price analysis, check to measure TRACON Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TRACON Pharmaceuticals is operating at the current time. Most of TRACON Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of TRACON Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TRACON Pharmaceuticals' price. Additionally, you may evaluate how the addition of TRACON Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is TRACON Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TRACON Pharmaceuticals. If investors know TRACON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TRACON Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.20) | Revenue Per Share 7.357 | Return On Assets (0.29) | Return On Equity (12.77) |
The market value of TRACON Pharmaceuticals is measured differently than its book value, which is the value of TRACON that is recorded on the company's balance sheet. Investors also form their own opinion of TRACON Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is TRACON Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TRACON Pharmaceuticals' market value can be influenced by many factors that don't directly affect TRACON Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TRACON Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if TRACON Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TRACON Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.